Table of Contents

Part 1 The artificial cell: Introduction to artificial cells: Concept, history, design, current status and future; Polymeric hydrophilic polymers in targeted drug delivery; The artificial cell design: Liposomes; The artificial cell design: Nanoparticles. Part 2 Cell engineering: The cutting edge: Apoptosis and therapeutic opportunity; Bone marrow stromal cells in myocardial regeneration and the role of cell signalling; Musculoskeletal tissue engineering with skeletal muscle-derived stem cells. Part 3 Artificial cells for cell therapy: Artificial cell for oral delivery of live bacterial cells for therapy; Artificial cells in liver disease; Artificial cells as a novel approach to gene therapy; Capillary devices for therapy. Part 4 The clinical relevance of artificial cells and cell engineering: Artificial cells in medicine: With emphasis on blood substitutes; Bone marrow stromal cells as ‘universal donor cells’ for myocardial regeneration therapy; Myocardial regeneration, tissue engineering and therapy; Kidney diseases and potentials of artificial cells; Engineered cells for treatment of diabetes; Drug delivery system for active brain targeting; Artificial cells in enzyme therapy with emphasis on tyrosinase for melanoma in mice; Stem cell and regenerative medicine: Commercial and pharmaceutical implications; Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): The mechanism, present therapy and therapeutic potential of cell-based therapy; Inflammatory bowel diseases: Current treatment strategies and potential for drug delivery using artificial cell microcapsules; Carrier-mediated and artificial-cell targeted cancer drug delivery.

About the Author

Dr Satya Prakash is Director of the Biomedical Technology and Cell Therapy Research Laboratory and Associate Professor of Biomedical Engineering (in the Faculty of Medicine) at the internationally renowned McGill University, Canada. Dr Prakash is highly regarded for his research into artificial cells, cell and tissue engineering, and more recently for his contribution to the development of controlled-release drug delivery systems.